Hepatitis News : Gilead Offers Egypt 99% Price Cut for Sovaldi
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis News » March 2014


emailprint

March 27, 2014

Gilead Offers Egypt 99% Price Cut for Sovaldi

Moving to combat mounting criticism over the sky-high cost of Sovaldi (sofosbuvir), Gilead Sciences has offered to supply its newest treatment for the hepatitis C virus (HCV) to Egypt at a 99 percent discount of the U.S. price, Reuters reports.

In Egypt, the blockbuster hep C drug will now cost about $900 for a 12-week course of treatment, a fraction of the $84,000 price tag for the same treatment in the United States.

The company’s offer will supply Sovaldi to Egypt’s government clinics, which are currently facing the highest prevalence rate of hepatitis C in the world—about 10 percent of the population has hep C. Egyptian officials say treatment will be made available to the public in the second half of 2014.

Gilead says it also plans to license its new therapy to Indian generic manufacturers, which will then supply lower cost versions of the drug to India. The company’s two pricing moves were made in order to help narrow the access gap for hepatitis C drugs among the world’s poorer nations.

However, U.S. lawmakers are still concerned about how the pharmaceutical company will address the high cost of the drug domestically.

To read the Reuters article, click here.

Search: Gilead, Sovaldi, sofosbuvir, Egypt, India, hepatitis C, HCV


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (4 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Should Medicaid limit access to new hep C drugs?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.